FormBlends Guides · FormBlends network
Handle the everyday parts of GLP-1 therapy with confidence, from the first shot on.
Twenty practical how-tos sourced to the labels: injection technique by site, travel, alcohol, surgery, pregnancy planning, switching, stopping and keeping muscle.
- 20
- long-form guides sourced to the four labels
- Long-form guides, each sourced to the four labels and dated.
- 24% vs 11%
- constipation on Wegovy 2.4 mg vs placebo
- Constipation on Wegovy versus placebo. Common, and manageable when you plan for it.
- 4 weeks
- minimum at each escalation step on Wegovy and Zepbound
- The shortest the labels allow at each dose step before moving up.
Start here
Three ways in, depending on what you need right now
- 01Injection site rotation plannerWhere to inject each week for 8 to 16 weeks: abdomen, thigh, upper arm, alternating sides and spots. Prints on one page.
- 02Alcohol on a GLP-1: what the labels say (almost nothing), what the trials found, and how to drink if you doThe GLP-1 labels say nothing about alcohol. That is not the same as saying it is fine.
- 03Browse injecting7 pages, most recently updated September 4, 2026
Interactive
The calculator
Each runs in your browser, shows its formula, and prints a dated assumptions note. Nothing you type leaves the page.
Reading
Start with these
Each page opens with a plain-English summary, a figure drawn from the data, the numbers that matter, and what it means if you're considering treatment.
Daily Life
Alcohol on a GLP-1: what the labels say (almost nothing), what the trials found, and how to drink if you do
You'll get: The GLP-1 labels say nothing about alcohol. That is not the same as saying it is fine.
The GLP-1 labels carry no alcohol warning, but three other warnings intersect with drinking. What the labels say, what one trial found, and how to drink.
Daily Life
Surgery, sedation and endoscopy on a GLP-1: the label aspiration warning and what the anaesthesia societies say to do
You'll get: Every GLP-1 label warns that food may stay in your stomach under anaesthesia or deep sedation, which risks inhaling it.
Every GLP-1 label warns about aspiration under general anaesthesia or deep sedation. The label text, the 2023 and 2024 society guidance, and what to do.
Daily Life
Nausea on a GLP-1: the label rates, when it peaks, and a management routine that clinicians actually recommend
You'll get: Nausea is the most common side effect on every GLP-1 label, reported by a quarter to nearly half of people in trials.
Nausea is the most common adverse reaction on every GLP-1 label. The trial rates, why escalation weeks are worst, what clinicians recommend, and red flags.
Daily Life
Keeping muscle on a GLP-1: what the body-composition substudies found and the protein and training evidence that answers them
You'll get: In the trial substudies, about a quarter to two fifths of the weight lost was lean mass. That is normal.
A quarter to two fifths of weight lost on semaglutide or tirzepatide in the trial substudies was lean mass. What that means, and what protects muscle.
Daily Life
When a dose step is not going well: what the labels say about slowing down, staying put and stepping back
You'll get: The labels allow a prescriber to delay a dose increase, stay at a lower maintenance dose, or step back down.
The Wegovy and Zepbound labels set escalation schedules and the options when a step is not tolerated: delay, hold, or step down. What they permit.
Live updates
What changed since this site was written
Sources checked October 23, 2026, refreshed every six hours.
Newest on PubMed
Papers indexed in the last year matching side effects and practical use (355 in total).
- Safety outcomes of semaglutide by chronic kidney disease severity in the FLOW trial
Kidney Int · October 20, 2026 · PubMed 42901325
- Real-world observational study evaluating metabolic and kidney outcomes in patients living with chronic kidney disease and type 2 diabetes mellitus with obesity prescribed tirzepatide
Diabet Med · October 19, 2026 · PubMed 42897718
- Tirzepatide use in adolescents with metabolic dysfunction-associated steatotic liver disease (MASLD): A case series
JPGN Rep · October 12, 2026 · PubMed 42865987
- Characterizing the adverse event profile of semaglutide: A comprehensive U.S. food and drug administration adverse event reporting system-based pharmacovigilance study
Clin Nutr ESPEN · October 12, 2026 · PubMed 42863671
- Severe Euglycemic Diabetic Ketoacidosis After Semaglutide-Associated Poor Intake Despite Empagliflozin Discontinuation: A Case Report
Int Med Case Rep J · October 6, 2026 · PubMed 42859665
FDA and enforcement tracker
FormBlends research feed, data as of September 4, 2026.
September 1, 2026 · Adverse-event report update
FDA GLP-1 concerns page updated: 990 adverse-event reports for compounded semaglutide and >730 for compounded tirzepatide (as of May 31, 2026); border screening and fake-pharmacy labelsAugust 28, 2026 · Label or price event
FDA approves Mounjaro (tirzepatide) to reduce MACE risk in adults with type 2 diabetes (SURPASS-CVOT)August 27, 2026 · Court decision
Fifth Circuit affirms summary judgment for FDA in both GLP-1 shortage cases (Nos. 25-10600 tirzepatide; 25-10758 semaglutide)August 24, 2026 · FDA warning letter
FDA warning letters to five peptide vendors: Peak Performance Peptides (735127), Royal Peptides (734884), NuScience Peptides (733652), Peptide Partners (735063), TXP Innovations dba Tex Peptides (735067)August 24, 2026 · FDA warning letter
FDA warning letter: TXP Innovations LLC dba Tex Peptides (Unapproved New Drugs/Misbranded)
Compounded price index
Median all-in cash price per 28 days across providers, as of September 3, 2026.
- semaglutide, month 1 at 0.25 mg/week
- $197
- median of 14 providers
- semaglutide, month 4 at 1 mg/week
- $199
- median of 13 providers
- tirzepatide, month 1 at 2.5 mg/week
- $268
- median of 14 providers
- tirzepatide, month 4 at 5 mg/week
- $299
- median of 12 providers
- September 3, 2026: Index, All, baseline 51 rows. First weekly snapshot. Changes against this baseline will be listed here with the date they were observed.
PubMed lists come from NCBI E-utilities and are not reviewed by us before they appear. Feeds are FormBlends Research data (CC BY 4.0); FormBlends sells compounded GLP-1 drugs and appears in the price index under the same rules as every other provider. Compounded drugs are not FDA approved.
Browse
Sections
20 pages across 4 sections, each sourced to a label, a trial or a dated manufacturer page.
Injecting
You'll get: 7 sourced pages, each with a plain-English opener
How to give a weekly semaglutide or tirzepatide injection in the abdomen, step by step, using the label...
Daily Life
You'll get: 7 sourced pages, each with a plain-English opener
The GLP-1 labels carry no alcohol warning, but three other warnings intersect with drinking. What the labels...
Planning
You'll get: 5 sourced pages, each with a plain-English opener
The Wegovy and Ozempic labels say to stop two months before a planned pregnancy. The Zepbound and Mounjaro...
Reference
You'll get: 1 sourced page, each with a plain-English opener
Sixty-eight terms a person on semaglutide or tirzepatide meets in the label, the device leaflets, the trial...
How these guides are written
Each guide starts from the FDA prescribing information for Zepbound, Mounjaro, Wegovy and Ozempic on DailyMed, then adds the trials or society guidance that answer the practical question the label leaves open. Where a step is general practice rather than label text, the guide says so and names the source. Where nothing reliable exists, the guide says that too. Compounded semaglutide and tirzepatide are not FDA approved and are not interchangeable with brand products; the guides say so wherever it matters.
What the guides are not
They are not a substitute for the instructions for use in your box or for your prescriber. They do not tell you what dose to take, when to escalate, or whether to stop. The rotation planner decides where to inject, never how much. If a guide and your prescriber disagree, your prescriber wins.